Bioventus Inc. (BVS) stock
Close on Nov 11, 2026Market cap $924.17MP/E 13.7Yield –
Bioventus Inc. grew revenue 3.9% to $585.64M over the twelve months to Sep 26, 2026. Operating income rose 34.5% to $56.73M, moving the operating margin from 7.5% to 9.7%. Free cash flow was $84.99M, up 58.9% from a year earlier. At the latest close the market valued the company at $924.17M, 13.7 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 26, 2026
Valuation
- Market cap
- $924.17M
- P/E ratio
- 13.7
- Price to sales
- 1.58
- Price to book
- 3.84
- Dividend yield
- –
- Free cash flow yield
- 9.20%
Fundamentals
- Revenue
- $585.64M
- Net income
- $57.30M
- EPS, diluted
- $0.80
- Free cash flow
- $84.99M
- Book value per share
- $3.32
- Diluted shares
- 72M
Trading
- Next earnings
- Mar 4, 2027 (estimated, before the open)
- Previous close
- $11.18
- Open
- $11.14
- Day's range
- $10.97 – $11.26
- Volume
- 463,285
- Average volume (20 days)
- 652,912
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 0.91
- 52-week range
- $6.47 – $15.89
- RSI (14 days)
- 34.9
- Volatility (1 year)
- 53.2%
- Relative volume
- 0.74×
- WACC
- 8.9%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BVS | S&P 500 | Difference | BVS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -15.9% | -2.4% | −13.5 pts | ||
| 3 months | -20.6% | -1.2% | −19.5 pts | ||
| Year to date | +47.7% | +12.3% | +35.4 pts | ||
| 1 year | +42.7% | +12.4% | +30.3 pts | ||
| 3 years | +212.2% | +78.8% | +133.4 pts | +46.2% | +21.4% |
| 5 years | -32.5% | +75.2% | −107.7 pts | -7.6% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Bioventus filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Bioventus
Surgical & Medical Instruments & Apparatus
Bioventus Inc. is a medical device company that develops and provides treatments for pain relief and musculoskeletal conditions. It operates through two reporting segments: U.S. and International. The company organizes its products into three clinical categories: Pain Treatments, Surgical Solutions, and Restorative Therapies. Offerings include hyaluronic acid injections and peripheral nerve stimulation systems, ultrasonic surgical systems and bone graft substitutes, and ultrasound fracture healing devices. Bioventus supplies these products to healthcare providers across physician offices, ambulatory surgical centers, and hospitals.
Company profile, executives and historyBioventus stock: common questions
What is Bioventus's stock price?
BVS closed at $10.99 on Nov 11, 2026, down 1.70% on the day. Over the past 52 weeks it traded between $6.47 and $15.89.
What is Bioventus's market cap?
Bioventus was worth $924.17M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BVS's P/E ratio?
BVS trades at 13.7 times earnings, based on diluted earnings per share of $0.80 over the twelve months to Sep 26, 2026.
How much revenue does Bioventus make?
Bioventus reported revenue of $585.64M for the twelve months to Sep 26, 2026, up 3.9% from a year earlier.
Does Bioventus pay a dividend?
No. Bioventus has not paid a cash dividend over the last twelve months.
When does Bioventus report earnings next?
Bioventus is expected to report Q4 FY2026 results on Mar 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has BVS stock performed over the past year?
Including dividends, BVS returned +42.7% over the past year, against +12.4% for the S&P 500.
How many BVS shares are sold short?
3M shares were sold short at the latest FINRA report, 5.06% of the float, or 6.6 days of average trading volume.
Who are Bioventus's competitors?
Companies most similar to Bioventus by business, industry and size include OFIX, AORT, ATRC, ATEC, ANIK.
See a number that looks wrong?